Login Register Cart 0
Research Article

白藜芦醇与辐射和热疗相结合诱导细胞凋亡并减弱MCF-7细胞的增殖。

卷 21, 期 2, 2021

发表于: 21 May, 2020

页: [142 - 150] 页: 9

弟呕挨: 10.2174/1566524020666200521080953

价格: $65

摘要

目的：在当前的体外研究中，我们试图研究白藜芦醇作为敏化剂联合放疗或热疗的可能作用。 背景：乳腺癌是女性最常见的恶性肿瘤，也是世界范围内最常见的恶性肿瘤之一。已经提出，仅使用非侵入性放射疗法不能消除癌细胞。热疗是一种辅助手段，主要通过凋亡和坏死诱导癌细胞死亡。但是，癌细胞也可能对此模式产生抵抗力。 目的：本研究的目的是确定白藜芦醇在热疗或放疗前用MCF-7细胞治疗时可能的凋亡增强作用。 方法：用不同剂量的白藜芦醇处理MCF-7癌细胞，达到IC50％。然后，将用达到浓度的白藜芦醇处理过的细胞暴露于放射线或高温下。使用流式细胞仪，MTT分析和实时PCR评估增殖，凋亡和促凋亡基因的表达。将每种联合疗法的结果与无白藜芦醇的放疗或热疗进行比较。 结果：辐射或热疗均可降低MCF-7细胞的活力。此外，Bax和caspase基因的调控增加，而Bcl-2基因表达减少。白藜芦醇增强了辐射和热疗对MCF-7细胞的作用。 结论：这项研究结果表明白藜芦醇能够诱导促凋亡基因的调控并减弱MCF-7细胞的活力。这可能表明白藜芦醇与放疗和热疗相结合的致敏作用。

关键词: 白藜芦醇，放射，热疗，MCF-7，乳腺癌，放疗，细胞凋亡，Bax，Bcl-2，Caspase 3，生存力。

« Previous Next »
[1]
DeSantis CE, Ma J, Goding Sauer A, Newman LA, Jemal A. Breast cancer statistics, 2017, racial disparity in mortality by state. CA Cancer J Clin 2017; 67(6): 439-48.
[http://dx.doi.org/10.3322/caac.21412] [PMID: 28972651]
[2]
Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. CA Cancer J Clin 2017; 67(1): 7-30.
[http://dx.doi.org/10.3322/caac.21387] [PMID: 28055103]
[3]
Camarillo IG, Xiao F, Madhivanan S, et al. Electroporation-based therapies for cancer. Woodhead Publishing 2014; pp. 55-102.
[http://dx.doi.org/10.1533/9781908818294.55]
[4]
Mondini M, Levy A, Meziani L, Milliat F, Deutsch E. Radiotherapy-immunotherapy combinations - perspectives and challenges. Mol Oncol 2020; 14(7): 1529-37.
[http://dx.doi.org/10.1002/1878-0261.12658] [PMID: 32112478]
[5]
Jamalzadeh L, Ghafoori H, Aghamaali M, Sariri R. Induction of apoptosis in human breast cancer MCF-7 cells by a semi-synthetic derivative of artemisinin: a caspase-related mechanism. Iranian J Biotechnol 2017; 15(3): 157-65.
[http://dx.doi.org/10.15171/ijb.1567] [PMID: 29845064]
[6]
Ahire V, Kumar A, Mishra KP, Kulkarni G. Ellagic acid enhances apoptotic sensitivity of breast cancer cells to γ-radiation. Nutr Cancer 2017; 69(6): 904-10.
[http://dx.doi.org/10.1080/01635581.2017.1339811] [PMID: 28718725]
[7]
Willers H, Dahm-Daphi J, Powell SN. Repair of radiation damage to DNA. Br J Cancer 2004; 90(7): 1297-301.
[http://dx.doi.org/10.1038/sj.bjc.6601729] [PMID: 15054444]
[8]
Luce A, Courtin A, Levalois C, et al. Death receptor pathways mediate targeted and non-targeted effects of ionizing radiations in breast cancer cells. Carcinogenesis 2009; 30(3): 432-9.
[http://dx.doi.org/10.1093/carcin/bgp008] [PMID: 19126655]
[9]
Ware MJ, Krzykawska-Serda M, Chak-Shing Ho J, et al. Optimizing non-invasive radiofrequency hyperthermia treatment for improving drug delivery in 4T1 mouse breast cancer model. Sci Rep 2017; 7(1): 43961.
[http://dx.doi.org/10.1038/srep43961] [PMID: 28287120]
[10]
Hamzehalipour Almaki J, Nasiri R, Idris A, Nasiri M, Abdul Majid FA, Losic D. Trastuzumab-decorated nanoparticles for in vitro and in vivo tumor-targeting hyperthermia of HER2+ breast cancer. J Mater Chem B Mater Biol Med 2017; 5(35): 7369-83.
[http://dx.doi.org/10.1039/C7TB01305A] [PMID: 32264187]
[11]
Notter M, Piazena H, Vaupel P. Hypofractionated re-irradiation of large-sized recurrent breast cancer with thermography-controlled, contact-free water-filtered infra-red-A hyperthermia: a retrospective study of 73 patients. Int J Hyperthermia 2017; 33(2): 227-36.
[http://dx.doi.org/10.1080/02656736.2016.1235731] [PMID: 27618745]
[12]
Zhang Z-Q, Song S-C. Multiple hyperthermia-mediated release of TRAIL/SPION nanocomplex from thermosensitive polymeric hydrogels for combination cancer therapy. Biomaterials 2017; 132: 16-27.
[http://dx.doi.org/10.1016/j.biomaterials.2017.03.049] [PMID: 28399459]
[13]
Zagar TM, Oleson JR, Vujaskovic Z, et al. Hyperthermia for locally advanced breast cancer. International journal of hyperthermia: the official journal of European Society for Hyperthermic Oncology. North American Hyperthermia Group 2010; 26(7): 618-24.
[http://dx.doi.org/10.3109/02656736.2010.501051]
[14]
Rethfeldt E, Becker M, Koldovsky P. Whole-body hyperthermia in the treatment of breast cancer. Breast Cancer Research: BCR 2001; 3(Suppl. 1): A51-1.
[http://dx.doi.org/10.1186/bcr379]
[15]
Luzhna L, Lykkesfeldt AE, Kovalchuk O. Altered radiation responses of breast cancer cells resistant to hormonal therapy. Oncotarget 2015; 6(3): 1678-94.
[http://dx.doi.org/10.18632/oncotarget.3188] [PMID: 25682200]
[16]
Hazra B, Ghosh S, Kumar A, Pandey BN. The prospective role of plant products in radiotherapy of cancer: a current overview. Front Pharmacol 2012; 2: 94.
[http://dx.doi.org/10.3389/fphar.2011.00094] [PMID: 22291649]
[17]
Sharma A, Kaur M, Katnoria JK, Nagpal AK. Polyphenols in food: cancer prevention and apoptosis induction. Curr Med Chem 2018; 25(36): 4740-57.
[http://dx.doi.org/10.2174/0929867324666171006144208] [PMID: 28990504]
[18]
Leon-Galicia I, Diaz-Chavez J, Albino-Sanchez ME, et al. Resveratrol decreases Rad51 expression and sensitizes cisplatin-resistant MCF-7 breast cancer cells. Oncol Rep 2018; 39(6): 3025-33.
[http://dx.doi.org/10.3892/or.2018.6336] [PMID: 29620223]
[19]
Joghatai M, Barari L, Mousavie Anijdan SH, Elmi MM. The evaluation of radio-sensitivity of mung bean proteins aqueous extract on MCF-7, hela and fibroblast cell line. Int J Radiat Biol 2018; 94(5): 478-87.
[http://dx.doi.org/10.1080/09553002.2018.1446226] [PMID: 29482484]
[20]
Kuršvietienė L, Stanevičienė I, Mongirdienė A, Bernatonienė J. Multiplicity of effects and health benefits of resveratrol. Medicina (Kaunas) 2016; 52(3): 148-55.
[http://dx.doi.org/10.1016/j.medici.2016.03.003] [PMID: 27496184]
[21]
Chimento A, De Amicis F, Sirianni R, et al. Progress to improve oral bioavailability and beneficial effects of resveratrol. Int J Mol Sci 2019; 20(6): 1381.
[http://dx.doi.org/10.3390/ijms20061381] [PMID: 30893846]
[22]
Ko JH, Sethi G, Um JY, et al. The Role of Resveratrol in Cancer Therapy. Int J Mol Sci 2017; 18(12)E2589
[http://dx.doi.org/10.3390/ijms18122589] [PMID: 29194365]
[23]
Yousef M, Vlachogiannis IA, Tsiani E. Effects of resveratrol against lung cancer: In vitro and In vivo studies. Nutrients 2017; 9(11): 1231.
[http://dx.doi.org/10.3390/nu9111231] [PMID: 29125563]
[24]
Pozo-Guisado E, Merino JM, Mulero-Navarro S, et al. Resveratrol-induced apoptosis in MCF-7 human breast cancer cells involves a caspase-independent mechanism with downregulation of Bcl-2 and NF-kappaB. Int J Cancer 2005; 115(1): 74-84.
[http://dx.doi.org/10.1002/ijc.20856] [PMID: 15688415]
[25]
Lee H, Park HJ, Park C-S, et al. Response of breast cancer cells and cancer stem cells to metformin and hyperthermia alone or combined. PLoS One 2014; 9(2)e87979
[http://dx.doi.org/10.1371/journal.pone.0087979] [PMID: 24505341]
[26]
Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 2001; 29(9)e45
[http://dx.doi.org/10.1093/nar/29.9.e45] [PMID: 11328886]
[27]
Keywan Mortezaee MN. Bagher Farhood, Amirhossein Ahmadi, Dheyauldeen Shabeeb, Ahmed Eleojo Musa, Resveratrol as an adjuvant for normal tissues protection and tumor sensitization. Curr Cancer Drug Targets 2019; •••: 19.
[28]
Morlé A, Garrido C, Micheau O. Hyperthermia restores apoptosis induced by death receptors through aggregation-induced c-FLIP cytosolic depletion. Cell Death Dis 2015; 6(2): e1633-3.
[http://dx.doi.org/10.1038/cddis.2015.12] [PMID: 25675293]
[29]
Fu Q, Huang T, Wang X, et al. Association of elevated reactive oxygen species and hyperthermia induced radiosensitivity in cancer stem-like cells. Oncotarget 2017; 8(60): 101560-71.
[http://dx.doi.org/10.18632/oncotarget.21678] [PMID: 29254186]
[30]
Roti Roti JL. Cellular responses to hyperthermia (40-46°C): cell killing and molecular events. Int J Hyperthermia 2008; 24(1): 3-15.
[http://dx.doi.org/10.1080/02656730701769841] [PMID: 18214765]
[31]
Chang C-H, Lee C-Y, Lu C-C, et al. Resveratrol-induced autophagy and apoptosis in cisplatin-resistant human oral cancer CAR cells: A key role of AMPK and Akt/mTOR signaling. Int J Oncol 2017; 50(3): 873-82.
[http://dx.doi.org/10.3892/ijo.2017.3866] [PMID: 28197628]
[32]
Mortezaee K, Najafi M, Farhood B, Ahmadi A, Shabeeb D, Musa AE. Resveratrol as an adjuvant for normal tissues protection and tumor sensitization. Curr Cancer Drug Targets 2020; 20(2): 130-45.
[http://dx.doi.org/10.2174/1568009619666191019143539] [PMID: 31738153]
[33]
Heo JR, Kim SM, Hwang KA, Kang JH, Choi KC. Resveratrol induced reactive oxygen species and endoplasmic reticulum stress-mediated apoptosis, and cell cycle arrest in the A375SM malignant melanoma cell line. Int J Mol Med 2018; 42(3): 1427-35.
[http://dx.doi.org/10.3892/ijmm.2018.3732] [PMID: 29916532]
[34]
Liu Q, Fang Q, Ji S, Han Z, Cheng W, Zhang H. Resveratrol-mediated apoptosis in renal cell carcinoma via the p53/AMP-activated protein kinase/mammalian target of rapamycin autophagy signaling pathway. Mol Med Rep 2018; 17(1): 502-8.
[PMID: 29115429]
[35]
Mukherjee S, Hussaini R, White R, et al. TriCurin, a synergistic formulation of curcumin, resveratrol, and epicatechin gallate, repolarizes tumor-associated macrophages and triggers an immune response to cause suppression of HPV+ tumors. Cancer Immunol Immunother 2018; 67(5): 761-74.
[http://dx.doi.org/10.1007/s00262-018-2130-3] [PMID: 29453519]
[36]
Rauf A, Imran M, Butt MS, Nadeem M, Peters DG, Mubarak MS. Resveratrol as an anti-cancer agent: A review. Crit Rev Food Sci Nutr 2018; 58(9): 1428-47.
[http://dx.doi.org/10.1080/10408398.2016.1263597] [PMID: 28001084]
[37]
Tino AB, Chitcholtan K, Sykes PH, Garrill A. Resveratrol and acetyl-resveratrol modulate activity of VEGF and IL-8 in ovarian cancer cell aggregates via attenuation of the NF-κB protein. J Ovarian Res 2016; 9(1): 84.
[http://dx.doi.org/10.1186/s13048-016-0293-0] [PMID: 27906095]
[38]
Tilborghs S, Corthouts J, Verhoeven Y, et al. The role of Nuclear Factor-kappa B signaling in human cervical cancer. Crit Rev Oncol Hematol 2017; 120: 141-50.
[http://dx.doi.org/10.1016/j.critrevonc.2017.11.001] [PMID: 29198328]
[39]
Colombo J, Jardim-Perassi BV, Ferreira JP, et al. Melatonin differentially modulates NF-KB expression in breast and liver cancer cells. Anticancer Agents Med Chem 2018; 18(12): 1688-94.
[40]
Xia L, Tan S, Zhou Y, et al. Role of the NFκB-signaling pathway in cancer. OncoTargets Ther 2018; 11: 2063-73.
[http://dx.doi.org/10.2147/OTT.S161109] [PMID: 29695914]
[41]
Xia Y, Shen S, Verma IM. NF-κB, an active player in human cancers. Cancer Immunol Res 2014; 2(9): 823-30.
[http://dx.doi.org/10.1158/2326-6066.CIR-14-0112] [PMID: 25187272]
[42]
Farhood B, Khodamoradi E, Hoseini-Ghahfarokhi M, et al. TGF-β in radiotherapy: Mechanisms of tumor resistance and normal tissues injury. Pharmacol Res 2020; 155104745
[http://dx.doi.org/10.1016/j.phrs.2020.104745] [PMID: 32145401]
[43]
Shi Q, Chen Y-G. The functional switch of TGF-β signaling in breast cancer. Oncotarget 2019; 10(17): 1604-5.
[http://dx.doi.org/10.18632/oncotarget.26715] [PMID: 30899430]
[44]
Mortezaee K, Najafi M, Farhood B, Ahmadi A, Shabeeb D, Musa AE. NF-κB targeting for overcoming tumor resistance and normal tissues toxicity. J Cell Physiol 2019; 234(10): 17187-204.
[http://dx.doi.org/10.1002/jcp.28504] [PMID: 30912132]
[45]
Vriend LEM, van den Tempel N, Oei AL, et al. Boosting the effects of hyperthermia-based anticancer treatments by HSP90 inhibition. Oncotarget 2017; 8(57): 97490-503.
[http://dx.doi.org/10.18632/oncotarget.22142] [PMID: 29228626]
[46]
Tu Y, Tian Y, Wu Y, Cui S. Clinical significance of heat shock proteins in gastric cancer following hyperthermia stress: Indications for hyperthermic intraperitoneal chemoperfusion therapy. Oncol Lett 2018; 15(6): 9385-91.
[http://dx.doi.org/10.3892/ol.2018.8508] [PMID: 29946371]
[47]
Daunys S, Matulis D, Petrikaitė V. Synergistic activity of Hsp90 inhibitors and anticancer agents in pancreatic cancer cell cultures. Sci Rep 2019; 9(1): 16177.
[http://dx.doi.org/10.1038/s41598-019-52652-1] [PMID: 31700053]
[48]
IJff M, van Oorschot B, Oei AL, et al. Enhancement of radiation effectiveness in cervical cancer cells by combining ionizing radiation with hyperthermia and molecular targeting agents. Int J Mol Sci 2018; 19(8): 2420.
[http://dx.doi.org/10.3390/ijms19082420] [PMID: 30115874]
[49]
Cardile V, Scifo C, Russo A, et al. Involvement of HSP70 in resveratrol-induced apoptosis of human prostate cancer. Anticancer Res 2003; 23(6C): 4921-6.
[PMID: 14981946]

Rights & Permissions Print Cite
Article Metrics
36
1
© 2024 Bentham Science Publishers | Privacy Policy